New heart catheter shows promise for AFib patients

NCT ID NCT05971693

Completed Disease control Sponsor: Biosense Webster, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called the OMNYPULSE catheter with the TRUPULSE generator to treat paroxysmal atrial fibrillation (a type of irregular heartbeat). The goal was to see if it is safe and effective at isolating the veins that carry blood from the lungs to the heart. 188 participants with symptomatic AFib were enrolled. The study measured safety events within 7 days and how well the procedure stopped abnormal electrical signals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

AZ Sint-Jan

Bruges, 8000, Belgium
AZORG campus Aalst Moorselbaan

Aalst, 9300, Belgium
Generale Regionale F. Miulli

Acquaviva delle Fonti, 70021, Italy
IKEM

Prague, 140 21, Czechia
Jessa Ziekenhuis - Campus Virga Jesse

Hasselt, 3500, Belgium
KBC Split

Split, 21000, Croatia
MVZ CCB Frankfurt und Main Taunus GbR

Frankfurt a.M., 60431, Germany
Maastricht UMC

Maastricht, 6229 HX, Netherlands
McGill University Health Centre

Montreal, Quebec, H3G 1A4, Canada
Montreal Heart Institute

Montreal, Quebec, H1T 1C8, Canada
Nemocnice na Homolce

Prague, 150 30 District 5, Czechia
Vilnius University Hospital Santariskiu Klinikos

Vilnius, 08661, Lithuania
Ziekenhuis Oost-Limburg

Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.